Avantor (AVTR) Q4 2020 earnings summary

Executive summary

• 2020 net sales rose 5.8% to $6.394B; organic growth was 5.6%, with gains led by biopharma, proprietary product mix and COVID-19-related demand.

• Mission-critical products and services span research through production; approximately 85% of net sales were recurring in nature.

Financial highlights

• FY 2020 net income was $116.6M versus $37.8M in 2019; operating income rose to $706.8M from $551.8M.

• Q4 net sales were $1,790.9M versus $1,524.0M in Q4 2019; net income was $51.6M and diluted EPS was $0.06.

• Operating cash flow reached $929.8M and free cash flow was $868.2M, versus $354.0M and $302.4M, respectively, in 2019.

• Adjusted EPS was $0.89 versus $0.58 in 2019; the annual shareholder message reported 54% growth.

Outlook and guidance

• Long-term value framework targets 4–6% organic growth, 50–100 bps annual margin expansion, mid-teens-plus EPS growth and strong free cash flow.

• More than $220M of annualized restructuring synergies were generated through year-end; management expected these to benefit 2021 and beyond.

• Priorities include expanding services and technology innovation, pursuing strategic M&A and supporting COVID-19 therapies and vaccines.